Reviva Pharmaceuticals Holdings EBIT

The latest EBIT for RVPH is $-23T as of June 2026. That compares with $-19M in the prior-year period — down 121974008.5% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Reviva Pharmaceuticals Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, RVPH's EBIT moved from $-19M to $-23T — a 121974008.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Reviva Pharmaceuticals Holdings's operating scale or balance-sheet position.

Against Healthcare companies, RVPH currently prints $-23T for EBIT, while the sector average sits near $110B. That is roughly 21337.5% below the sector mean. Large gaps often invite a closer look at Reviva Pharmaceuticals Holdings's growth, margins, and balance sheet.

A EBIT figure of $-23T for RVPH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting RVPH's EBIT ($-23T), review year-over-year change from $-19M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.